Advertisement
COO vs ZBH
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a StrongBuy and ZBH is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COO’s FA Score shows that 1 FA rating(s) are green whileZBH’s FA Score has 1 green FA rating(s).
- COO’s FA Score: 1 green, 4 red.
- ZBH’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COO’s TA Score shows that 4 TA indicator(s) are bullish while ZBH’s TA Score has 5 bullish TA indicator(s).
- COO’s TA Score: 4 bullish, 5 bearish.
- ZBH’s TA Score: 5 bullish, 4 bearish.
Price Growth
COO (@Pharmaceuticals: Other) experienced а +15.41% price change this week, while ZBH (@Medical/Nursing Services) price change was +7.02% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.77%. For the same industry, the average monthly price growth was -0.19%, and the average quarterly price growth was -16.05%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.74%. For the same industry, the average monthly price growth was +2.57%, and the average quarterly price growth was -15.61%.
Reported Earning Dates
COO is expected to report earnings on Sep 02, 2026.
ZBH is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-2.77% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-0.74% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| COO | ZBH | COO / ZBH | |
| Capitalization | 13.4B | 17.3B | 77% |
| EBITDA | 1.08B | 2.31B | 47% |
| Gain YTD | -16.234 | -0.052 | 31,306% |
| P/E Ratio | 58.18 | 23.22 | 251% |
| Revenue | 4.15B | 8.41B | 49% |
| Total Cash | 125M | 424M | 29% |
| Total Debt | 2.5B | 7.47B | 33% |
COO | ZBH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 57 | 55 | |
P/E GROWTH RATING 1..100 | 15 | 39 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZBH's Valuation (9) in the Medical Specialties industry is significantly better than the same rating for COO (75). This means that ZBH’s stock grew significantly faster than COO’s over the last 12 months.
ZBH's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as COO (100). This means that ZBH’s stock grew similarly to COO’s over the last 12 months.
ZBH's SMR Rating (100) in the Medical Specialties industry is in the same range as COO (100). This means that ZBH’s stock grew similarly to COO’s over the last 12 months.
ZBH's Price Growth Rating (55) in the Medical Specialties industry is in the same range as COO (57). This means that ZBH’s stock grew similarly to COO’s over the last 12 months.
COO's P/E Growth Rating (15) in the Medical Specialties industry is in the same range as ZBH (39). This means that COO’s stock grew similarly to ZBH’s over the last 12 months.
| COO | ZBH | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 52% | 2 days ago 59% |
| Stochastic ODDS (%) | 2 days ago 57% | 2 days ago 59% |
| Momentum ODDS (%) | 2 days ago 59% | 2 days ago 60% |
| MACD ODDS (%) | 2 days ago 50% | 2 days ago 64% |
| TrendWeek ODDS (%) | 2 days ago 55% | 2 days ago 58% |
| TrendMonth ODDS (%) | 2 days ago 49% | 2 days ago 54% |
| Advances ODDS (%) | 6 days ago 57% | 6 days ago 64% |
| Declines ODDS (%) | 9 days ago 60% | 15 days ago 57% |
| BollingerBands ODDS (%) | 2 days ago 59% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 71% | 2 days ago 55% |
Advertisement